论文部分内容阅读
为了观察华蟾素治疗慢性ＨＢＶ携带者及慢性乙型肝炎使乙肝病毒复制指标转阴的作用。我们选择ＨＢＶ 携带者及慢性乙型肝炎６０ 例。治疗组用华蟾素４ｍｌ，肌注，日一次，连用３个月，对照组不用华蟾素治疗。结果治疗组ＨＢｓＡｇ 阳性者３０ 例中转阴１ 例，对照组无转阴者。ＨＢｅＡｇ 阳性１６ 例中转阴８ 例，占（５０ ％ ） ，与对照组比Ｐ＜ ０－０２５；ＰｒｅＳ２ 阳性者２３ 例中转阴１１ 例占（４７－８２ ％ ） 与对照组比Ｐ＜ ０－０２５ 。结论：华蟾素可提高机体免疫力，注射３ 个月约半数患者可使ＨＢｅＡｇ ＰｒｅＳ２ 转阴。
In order to observe the role of cinobufacini in the treatment of chronic HBV carriers and chronic hepatitis B virus hepatitis B virus replication indicators negative. We choose 60 cases of HBV carriers and chronic hepatitis B. Treatment group with cinobufacini 4ml, intramuscular injection, once a day, once every 3 months, the control group without cinobufotalin treatment. Results In the treatment group, 30 cases of HBsAg positive were negative in 1 case, while those in control group had no negative negative. HBeAg positive in 16 cases of negative in 8 cases, accounting for (50%), compared with the control group P <0-025; Pre-S2 positive in 23 cases of negative in 11 cases (47-82%) compared with the control group P <0 -025. Conclusion: Cinobufacini can improve the body immunity, about 3 months after injection of about half of HBeAg Pre-S2 patients can make negative.